Loading Events

« All Events

BioBusiness Insights: Achieving Global Reach & Partnering

September 22 @ 9:00 am - 10:00 am AEST

This is Session 5 in the BioBusiness Insights: Opportunities in Regenerative Medicine series. Find out more about about all six sessions, and register for the series at a reduced rate below.

In this session, Dr Kilian Kelly will present on Cynata Therapeutics’s experience in achieving global reach and partnering. Kilian will provide a first-hand account of Cynata’s pathway to license agreement with FUJIFILM for an allogeneic iPS-derived cell therapy for serious complications following bone marrow transplants.

What made Cynata’s approach so successful? And what were the challenges and obstacles they had to navigate to secure a global partnership?

Session 5 Details

Date: Tuesday 22 September 2020
Time: 9:00 am – 10:00 am AEST
Format:  This event will be delivered on a virtual platform – you will receive a link to join via a confirmation email following registration.
Registration:
Single session: Members $35; Non-members $45
Complete series (six sessions): Members $150; Non-members $210
Unsure if your organisation is a member? Check our member directory.

Registered? Submit a question for Session 5 ahead of time.

Speaker

Dr Kilian Kelly, Chief Operating Officer, Cynata Therapeutics

Series Facilitator

Silvio Tiziani, CEO, CCRM Australia

 

BioBusiness Insights is delivered in collaboration with the Centre for Commercialization of Regenerative Medicine (CCRM) Australia.

Thanks to our Premier Sponsor for this event series, the State Government of Victoria.

Thanks to our Supporting Sponsor for this event series, Cortellis.

Dr Kilian Kelly, Chief Operating Officer, Cynata Therapeutics

Dr Kilian Kelly has approximately 15 years’ experience in pharmaceutical/biotechnology research and development, in both commercial and academic settings. His previous appointments include Senior Director, Drug Development at Biota Pharmaceuticals (NASDAQ: BOTA), Vice President, Regulatory and Clinical at Mesoblast Limited (ASX:MSB), and various regulatory affairs and project management positions with Kendle International (now INC Research), Amgen (NASDAQ: AMGN) and Astrazeneca (LSE: AZN). Dr Kelly holds a Masters in Pharmacy from Robert Gordon University, Aberdeen and a PhD in Pharmaceutical Sciences from Strathclyde University, Glasgow. He is a registered pharmacist and a member of the Royal Pharmaceutical Society, The Organisation for Professionals in Regulatory Affairs (TOPRA) and the Regulatory Affairs Professionals Society (RAPS).

Silvio Tiziani, CEO, CCRM Australia

Silvio Tiziani has played a key role in the establishment of Centre for Commercialisation of Regenerative Medicine (CCRM) Australia with the support of Canada’s CCRM, the Victorian Government and MTPConnect. Silvio is also Director, External Strategy and Planning at the Australian Regenerative Medicine Institute (ARMI). Silvio’s extensive knowledge of the research landscape is well utilised with his networks within the industry, international organisations and state and federal governments.
Silvio has extensive experience in private and public organisations, with a focus on laboratory-based services in government, private organisations, healthcare and research/academia.
In addition to qualifications that include a Bachelor of Science from Swinburne University and a Masters of Business Administration from Monash University, Silvio is also a graduate of the Australian Institute of Company Directors (GAICD). Silvio has extensive experience in financial analysis and budget management, business development, strategic planning and corporate governance along with strong interpersonal skills to lead staff.
Silvio also chairs the Ausbiotech Regenerative Medicine Advisory Group. Comprising leading representatives from industry and academia within the Australian regenerative medicine the Group provides specialist advice to Ausbiotech, Australia’s member-based biotechnology organisation, a peak body that promotes the global growth of Australian biotechnology.

Tickets

Member - Virtual Ticket$35.00
Member - Series$150.00
Non Member - Virtual Ticket$45.00
Non Member - Series$210.00

Details

Date:
September 22
Time:
9:00 am - 10:00 am
Cost:
$35 - $210
Event Category:

Contact

BioMelbourne Network
Phone:
+61 3 9667 8181
Email:
info@biomelbourne.org

Home

News & opinion

Member Directory

Events